Clinical trial
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in…
NCT00066469 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00066469 |
|---|---|
| Title | Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation |
| Official title | Phase II Study of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults With B-lymphocyte Antigen CD20 (CD20) Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT) |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoproliferative Disorder |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cyclophosphamide, methylprednisolone, prednisone |
| Enrollment | 55 |
| Start date | Apr 1, 2004 |
| Primary completion | Oct 1, 2009 |
| Completion | Dec 31, 2013 |
| First posted | Aug 7, 2003 |
| Last update posted | Aug 6, 2019 |
| Countries | Australia, Canada, New Zealand, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: